Celsion Corporation (NASDAQ: CLSN), which is involved in the DNA-based immunotherapy space, has seen its stock make significant gains so far this year.
At this point, the Celsion stock is up by as high as 150% and in such a situation, it might be a good idea for investors to take a closer look at the company. One of the most important triggers for the stock came about on February 22 when it announced that one of its products was awarded Fast Track Designation by the United States Food and Drug Administration.
The product in question is GEN 1, which is currently in Phase 2 of clinical development. GEN 1 is meant for treating individuals suffering from the advanced variant of ovarian cancer. Celsion had deployed its proprietary delivery system platform TheraPlas in order to develop the product. It is a key milestone for the company and one that could prove to be a major boost for the stock.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.